Investing.com - Can Fite Biopharma ADR reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Can Fite Biopharma ADR announced earnings per share of $-0.135 on revenue of $215K. Analysts polled by Investing.com anticipated EPS of $-0.155 on revenue of $220K.
Can Fite Biopharma ADR shares are up 7% from the beginning of the year and are trading at $1.880 , down-from-52-week-high.They are under-performing the CAC 40 which is up 20.08% from the start of the year.
Can Fite Biopharma ADR shares gained 1.62% in intra-day trade the report.
Can Fite Biopharma ADR follows other major Healthcare sector earnings this month
Can Fite Biopharma ADR's report follows an earnings beat by Merck ADR on Thursday, August 5, 2021, who reported EPS of $0.5304 on revenue of $5.77B, compared to forecasts EPS of $0.4897 on revenue of $5.63B.
Hoya Corp had beat expectations on Thursday, July 29, 2021 with second quarter EPS of $1.02 on revenue of $1.44B, compared to forecast for EPS of $0.8576 on revenue of $1.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar